Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (video)
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?
Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Geoffrey Oxnard: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing
Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for?"
Dr. Greg Riely: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Drs. Ross Camidge and Corey Langer: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?
Dr. Greg Riely: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?
Dr. Heather Wakelee on "Which molecular marker tests do you seek?"
Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (audio)
Dr. Karen Kelly: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. David Spigel: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Sarah Goldberg on "Which patients do you send molecular marker testing for?"
Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. David Spigel on "Which molecular marker tests do you seek?"
Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Different Lung Cancer Subtypes - Histology
What is the Role of Bevacizumab in Stage IV NSCLC?
Histology-Specific Regimens - Adenocarcinoma
Histology-Specific Regimens - Squamous
Histology-Specific Recommendations - Large-Cell Neuroendocrine
Anatomic Pathology with Dr. Joanna Walsh
Scopri di più
Cerca
